VALN
Price:
$6.02
Market Cap:
$437.41M
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine can...[Read more]
Industry
Biotechnology
IPO Date
2021-05-05
Stock Exchange
NASDAQ
Ticker
VALN
According to Valneva SE’s latest financial reports and current stock price. The company's current PE Ratio is -11.36. This represents a change of 73.22% compared to the average of -6.56 of the last 4 quarters.
The mean historical PE Ratio of Valneva SE over the last ten years is -110.50. The current -11.36 PE Ratio has changed 928.01% with respect to the historical average. Over the past ten years (40 quarters), VALN's PE Ratio was at its highest in in the December 2019 quarter at 1.21K. The PE Ratio was at its lowest in in the September 2019 quarter at -15295.79.
Average
-110.50
Median
-42.08
Minimum
-1238.85
Maximum
568.18
Discovering the peaks and valleys of Valneva SE PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 285.26%
Maximum Annual PE Ratio = 568.18
Minimum Annual Increase = -487.41%
Minimum Annual PE Ratio = -1238.85
Year | PE Ratio | Change |
---|---|---|
2023 | -12.82 | 33.93% |
2022 | -9.57 | -85.25% |
2021 | -64.90 | 113.10% |
2020 | -30.46 | -97.54% |
2019 | -1238.85 | -318.04% |
2018 | 568.18 | -487.41% |
2017 | -146.66 | 285.26% |
2016 | -38.07 | -55.63% |
2015 | -85.80 | 86.14% |
2014 | -46.09 | 46.29% |
The current PE Ratio of Valneva SE (VALN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-29.10
5-year avg
-271.32
10-year avg
-110.50
Valneva SE’s PE Ratio is less than Advaxis, Inc. (-0.00), less than NuCana plc (-0.20), less than Sage Therapeutics, Inc. (-1.07), less than SELLAS Life Sciences Group, Inc. (-2.04), greater than Third Harmonic Bio, Inc. (-33.09), less than Cullinan Oncology, Inc. (-6.95), greater than Edgewise Therapeutics, Inc. (-23.81), less than Rallybio Corporation (-0.66), less than Monte Rosa Therapeutics, Inc. (-3.41), greater than Tyra Biosciences, Inc. (-17.40), less than C4 Therapeutics, Inc. (-4.19), less than Stoke Therapeutics, Inc. (-8.15), greater than Revolution Medicines, Inc. (-14.69), less than Opthea Limited (-1.48), less than Inhibrx, Inc. (0.15), less than Mineralys Therapeutics, Inc. (-4.99), less than Eliem Therapeutics, Inc. (-3.91), less than Anebulo Pharmaceuticals, Inc. (-5.77), less than Nuvation Bio Inc. (-1.41), less than Instil Bio, Inc. (-3.20), less than Connect Biopharma Holdings Limited (-2.98), less than Neoleukin Therapeutics, Inc. (-0.98), less than Graphite Bio, Inc. (-0.13),
Company | PE Ratio | Market cap |
---|---|---|
-0.00 | $852.67K | |
-0.20 | $7.88M | |
-1.07 | $482.30M | |
-2.04 | $78.49M | |
-33.09 | $605.37M | |
-6.95 | $1.04B | |
-23.81 | $2.77B | |
-0.66 | $45.64M | |
-3.41 | $383.58M | |
-17.40 | $1.27B | |
-4.19 | $455.55M | |
-8.15 | $797.09M | |
-14.69 | $7.71B | |
-1.48 | $594.00M | |
0.15 | $253.18M | |
-4.99 | $601.69M | |
-3.91 | $555.26M | |
-5.77 | $53.94M | |
-1.41 | $732.32M | |
-3.20 | $382.10M | |
-2.98 | $68.48M | |
-0.98 | $8.20M | |
-0.13 | $185.19M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Valneva SE using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Valneva SE or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Valneva SE's PE Ratio?
How is the PE Ratio calculated for Valneva SE (VALN)?
What is the highest PE Ratio for Valneva SE (VALN)?
What is the 3-year average PE Ratio for Valneva SE (VALN)?
What is the 5-year average PE Ratio for Valneva SE (VALN)?
How does the current PE Ratio for Valneva SE (VALN) compare to its historical average?